Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1752 (LINC01752)
- Target
- LINC01752
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA)
01
Overview
LINC01752 encodes a long intergenic non-protein coding RNA, a member of the lincRNA family. LincRNAs are a subclass of long non-coding RNAs that do not overlap protein-coding regions and typically function in transcriptional regulation, chromatin remodeling, and RNA stabilization. LINC01752 is differentially expressed across breast cancer subtypes, serving as an angiogenesis-inhibiting tumor suppressor in luminal breast cancer and triple-negative breast cancer, where it attenuates migration, invasion, and metastasis by influencing gene networks and interacting with the tumor suppressor RBM47. Though not a direct therapeutic target, its variable expression is relevant for cancer biology and may inform future biomarker development for some malignancies.
02
Mechanism of action
Not applicable for drugs; LINC01752 itself operates by interacting with protein partners (e.g., RBM47, a tumor suppressor) and modulating biological processes, most notably inhibiting angiogenesis and promoting tumor suppression in specific cancer subtypes
03
Biological functions
Regulation of gene expressionChromatin remodelingModulation of cell migration and invasion (as shown for related lincRNAs in cancer contexts)Regulation of cell cycle and proliferation (as reported for some functionally similar lncRNAs)
04
Disease associations
Cancer (especially breast cancer subtypes; upregulated in luminal breast cancer, downregulated in triple-negative breast cancer, associated with suppression of tumor migration, invasion, metastasis, and angiogenesis)Emerging evidence for roles in other cancers (prostate, esophageal, gastric, and glioma per the broader literature, though gene-specific evidence may be limited)
05
Safety considerations
None reported for direct targeting, as LINC01752 is not currently a therapeutic target. For lncRNAs in general, challenges include off-target effects, delivery, and tissue specificity if therapies are developed
06
Biomarkers
Potential use as a biomarker in cancer, specifically in breast cancer subtype stratification and prognosis (as related studies indicate differential expression)
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 1752 (LINC01752).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1752 (LINC01752).